The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review
| Autor: | O. I. Restrepo, A. C. Avellaneda, C. E. Pinzón, C. Rueda, A. M. Osorio |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Adult
medicine.medical_specialty MEDLINE Vulvovaginal atrophy Vulva 03 medical and health sciences Estriol levels Endometrium 0302 clinical medicine Internal medicine Medicine Humans 030212 general & internal medicine Adverse effect Aged Gynecology Aged 80 and over 030219 obstetrics & reproductive medicine Postmenopausal women business.industry Estriol Systematic literature review Obstetrics and Gynecology General Medicine Hydrogen-Ion Concentration Middle Aged Female Urogenital Diseases Clinical trial Postmenopause Administration Intravaginal Systematic review Vagina Female Atrophy business hormones hormone substitutes and hormone antagonists |
| Zdroj: | Universidad de La Sabana Intellectum Repositorio Universidad de La Sabana Repositorio Universidad de la Sabana Universidad de la Sabana instacron:Universidad de la Sabana |
| Popis: | 11 páginas Objectives: To evaluate the efficacy and safety of estriol for the treatment of vulvovaginal atrophy in postmenopausal women. Methods: A systematic literature review was performed. We searched the following electronic databases: Medline, Cochrane, Embase, Lilacs, CINHAL and Google Scholar. The studies selected included controlled clinical trials and quasi-experimental studies. Selections were made in pairs and independently, first by title and abstract and then complete texts. Results: We identified 188 studies, 22 of which met the inclusion criteria; 13 were controlled clinical trials and nine were quasi-experimental, and 1217 women were included. These studies confirmed the efficacy of local estrogens to treat symptoms of vulvovaginal atrophy with few adverse effects reported. Following treatment, serum estriol levels rose, peaking at 1 h. At the 6-month follow-up, there was no increase in serum estriol in treated women. Conclusions: The available evidence (of low and moderate quality) shows that, when administered vaginally, estriol preparations appear to be safe for women who have risk factors related to systemic estrogen therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|